CXCR4 and cancer: Further evidence that CXCL12 is not the cognate survival ligand in CXCR4+ cancer cells was provided by Dwinell et al. who found that CXCL12 is transcriptionally silenced in six of eight breast cancer cell lines including MDA-MB-231 [42].